Cancer Drugs Approved Quickly Often Fail To Measure Up Later
Regulators give many cancer drugs a fast track to market while requiring drugmakers to do more studies after approval. Researchers have found the follow-up studies frequently come up short.
Cancer drugs that speed onto the market based on encouraging preliminary studies often don't show clear benefits when more careful follow-up trials are done, according to research published Tuesday.
These cancer drugs are granted accelerated approval to give patients faster access to the treatments and to allow drug companies to reap the economic rewards sooner. As a condition of this process, the Food and Drug Administration requires drug companies to conduct more research, to confirm whether the medications actually work and are safe.
In 2018, granted accelerated approval and touted that only five had been dug deeper to see what happened with the rest.
